MDxHealth, Inc. And Cerba HealthCare Announce Collaboration Agreement For SelectMDx Commercialization

Partnership increases patient access throughout France, Belgium and Luxembourg

IRVINE, CA, and ZWIJNAARDE, BELGIUM - July 25th, 2016 - MDxHealth SA (Euronext: MDXH.BR) and Cerba HealthCare Belgium, announced today that they have signed a Collaboration Agreement to bring MDxHealth’s SelectMDx™ for Prostate Cancer test to urology practitioners in France, Belgium and Luxembourg.

Under the terms of this two-year agreement, Cerba HealthCare Belgium will offer the SelectMDx test through its laboratory network in France, Belgium and Luxembourg. During the initial phase of the agreement, samples will be analyzed at MDxHealth’s service-testing laboratory in Nijmegen, The Netherlands. The agreement will then move into a second phase, whereby the SelectMDx test will be transferred to the Molecular Biology Department of Cerba HealthCare’s laboratory CRI in Zwijnaarde, Belgium.

“This exciting partnership with Cerba dramatically increases access to SelectMDx in Europe,” stated Dr. Jan Groen, Chief Executive Officer, MDxHealth, “Cerba is a leading healthcare provider specializing in the delivery of advanced diagnostic assays and serving 15,000 patients per day through its 5,000 customers worldwide, who will now have access to SelectMDx.”

“Compared to our current PCA3 marker, SelectMDx supports a broader segment of patients at risk of prostate cancer,” added Dr. Els Decoster, Head of Molecular Biology and R&D at CRI. “We will therefore replace PCA3 with SelectMDx in our molecular test portfolio.”

About SelectMDx for Prostate Cancer

Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive ‘liquid biopsy’ method to assess a man’s risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by approximately 50%, thereby reducing healthcare costs. For more information, visit our website: mdxhealth.com.

About Cerba HealthCare

Cerba HealthCare is a European healthcare provider headquartered in Paris, France and operating through a network of 300 laboratories and 150 specimen collection centers. Its three main activities are routine medical lab services with a geographical focus on France, Belgium and Luxembourg, specialized medical lab services for patients across Europe, Africa and Asia, and global central lab services in clinical trials for pharmaceutical and biotechnology developers across the world. Recently the group diversified in the veterinary biology market by creating Cerba Vet, a dedicated entity. For more information, visit www.cerbahealthcare.com.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

MORE ON THIS TOPIC